Literature DB >> 22504145

NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain.

Kristin E Smith1, Mona Boules, Katrina Williams, Elliott Richelson.   

Abstract

Neurotensin (NT) analogs, NT69L, NT72, and NT79, differentially bind the two major neurotensin receptors, NTS1 and NTS2, to elicit effects similar to those of endogenous NT, including analgesia. Previous data strongly suggest NTS2 as the main receptor involved in NT- and NT analog-mediated visceral analgesia. However, this idea has yet to be confirmed with the use of mice lacking the NTS2 receptor. Here we use the writhing assay, a model of visceral pain, to investigate the analgesic effects of NT69L (binds NTS1 and NTS2 equally), NT79 (NTS2-selective), NT72 (NTS1 selective) and levocabastine (NTS2-selective) in WT, NTS1 knock-out, and NTS2 knock-out mice. Additionally, we investigate the role of NTS2 in the development of tolerance to NT69L-mediated visceral analgesia. All three NT analogs reduced writhing in the WT mice. NT79 and levocabsatine reduced writhing in the NTS1(-/-) mice while NT69L and NT72 showed significant analgesic effect in the NTS2(-/-) mice. In conclusion, the data shows that (1) both NTS1 and NTS2 are involved in mediating visceral analgesia and their respective roles appear to be NT analog-dependent; (2) NTS1 may inhibit NTS2-mediated analgesia; and (3) NTS2 is necessary for the development of tolerance to NT69L-mediated analgesia.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504145     DOI: 10.1016/j.bbr.2012.03.044

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  14 in total

Review 1.  Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.

Authors:  Laura E Schroeder; Gina M Leinninger
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-27       Impact factor: 5.187

2. 

Authors:  Laura E Schroeder; Ryan Furdock; Cristina Rivera Quiles; Gizem Kurt; Patricia Perez-Bonilla; Angela Garcia; Crystal Colon-Ortiz; Juliette Brown; Raluca Bugescu; Gina M Leinninger
Journal:  Neuropeptides       Date:  2019-05-06       Impact factor: 3.286

3.  Identification of N-{[6-chloro-4-(2,6-dimethoxyphenyl)quinazolin-2-yl]carbonyl}-l-leucine (NTRC-808), a novel nonpeptide chemotype selective for the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Danni L Harris; Sanju Narayanan; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2014-11-24       Impact factor: 2.823

4.  In Search of the Optimal Macrocyclization Site for Neurotensin.

Authors:  Marc Sousbie; Élie Besserer-Offroy; Rebecca L Brouillette; Jean-Michel Longpré; Richard Leduc; Philippe Sarret; Éric Marsault
Journal:  ACS Med Chem Lett       Date:  2018-01-29       Impact factor: 4.345

5.  Brain corticotropin-releasing factor signaling: Involvement in acute stress-induced visceral analgesia in male rats.

Authors:  Muriel Larauche; Nabila Moussaoui; Mandy Biraud; Won Ki Bae; Henri Duboc; Mulugeta Million; Yvette Taché
Journal:  Neurogastroenterol Motil       Date:  2018-10-09       Impact factor: 3.598

6.  Neurotensin and its receptors in the control of glucose homeostasis.

Authors:  Jean Mazella; Sophie Béraud-Dufour; Christelle Devader; Fabienne Massa; Thierry Coppola
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-26       Impact factor: 5.555

7.  Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.

Authors:  James B Thomas; Angela M Giddings; Robert W Wiethe; Srinivas Olepu; Keith R Warner; Philippe Sarret; Louis Gendron; Jean-Michel Longpre; Yanan Zhang; Scott P Runyon; Brian P Gilmour
Journal:  J Med Chem       Date:  2014-06-05       Impact factor: 7.446

8.  Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Robert W Wiethe; Srinivas Olepu; Keith R Warner; Philippe Sarret; Louis Gendron; Jean-Michel Longpre; Yanan Zhang; Scott P Runyon; Brian P Gilmour
Journal:  J Med Chem       Date:  2014-08-26       Impact factor: 7.446

9.  Morphological evidence for a neurotensinergic periaqueductal gray-rostral ventromedial medulla-spinal dorsal horn descending pathway in rat.

Authors:  Jian Wang; Hua Zhang; Yu-Peng Feng; Hua Meng; Li-Ping Wu; Wen Wang; Hui Li; Ting Zhang; Jin-Shan Zhang; Yun-Qing Li
Journal:  Front Neuroanat       Date:  2014-10-09       Impact factor: 3.856

10.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.